Background Some countries fortify fl our with folic acid to prevent neural tube defects but others do not, partly because of concerns about possible cancer risks. We aimed to assess any eff ects on site-specifi c cancer rates in the randomised trials of folic acid supplementation, at doses higher than those from fortifi cation.
Introduction
Results from epidemiological studies of pregnant women showed that the intake of folate and the plasma concentration of folate early in pregnancy were both inversely associated with the incidence of neural tube defects, suggesting protection. [1] [2] [3] Non-randomised 4,5 and random ised 6, 7 intervention trials confi rmed a protective eff ect. Folate is now routinely recommended as a supplement before and during pregnancy. 8 Furthermore, population-wide folate fortifi cation of fl our for prevention of neural tube defects has been mandatory since 1998 in North America, resulting in a two-fold increase in population plasma concentrations of folate. 9, 10 It is also mandatory in some other countries, 9 including Chile, Argentina, Brazil, South Africa, and Australia; [11] [12] [13] but not in New Zealand or in western European countries, partly because of concerns about possible adverse eff ects on cancer incidence or prognosis. [13] [14] [15] Results from epidemiological studies in other adult popu lations have also shown inverse (ie, apparently protective) associations of folate intake, and consequently of plasma concentrations of folate, with the incidence of cardiovascular disease 16, 17 and colorectal cancer. 18 To test whether any real protective eff ect exists against cardiovascular disease, placebo-controlled trials of about 5 years of folic acid supplementation were undertaken in some 47 000 adults at high risk of vascular disease, and a collaborative meta-analysis of individual patient data on cancer incidence from all these trials was agreed prospectively in 2004, before any results emerged. 19, 20 These trials did not suggest any protective eff ect of folic acid supplementation against cardiovascular disease or against mortality from any cause during the scheduled trial treatment period. 20 To test whether there is any real protective eff ect against progression of colorectal adenomas, another three such trials [21] [22] [23] were undertaken in about 3000 patients. One of these trials, the Aspirin and Folic Acid Polyp Prevention Study (AFPPS), 21 reported in 2007 unexpected increases in the incidence of advanced colorectal adenomas and of prostate cancer during 7 years of treatment with folic acid. Also in 2007, it was suggested that transient increases in colorectal cancer incidence in Canada and the USA during 1996-98 might have been due to the 1996-98 introduction of folic acid fortifi cation programmes in North America. 24 Taken together, these reports (and awareness that anti-folate drugs such as methotrexate are used for the treatment of some cancers) prompted concerns about possible risks of cancer associated with folic acid supplements and folic acid fortifi cation. Studies in animals had previously suggested the possibility that high intakes of folate could suppress the development of early lesions in normal tissue, but enhance the growth of established neoplasms. 25 To see whether, in aggregate, the randomised trials of folic acid show an increase or decrease in cancer risk over a period of just a few years, we present collaborative meta-analyses of site-specifi c cancer incidence during the scheduled treatment period among 50 000 individuals from all available large cardiovascular and adenoma trials. We do not address the question of whether any eff ects on cancer incidence will emerge some years or decades after the trials have ended.
Methods

Trial eligibility
We identifi ed trials by searching PubMed using the search terms "randomized trials", "folic acid", "B-vitamins" or "homocysteine-lowering treatment", and by scanning reference lists of trial reports (appendix p 3). Trials were eligible for inclusion if (1) at least one randomised comparison was folic acid versus placebo with scheduled treatment duration of at least 1 year (irrespective of whether any other treatment was tested factorially); (2) the trial included at least 500 participants; and (3) data on cancer incidence had been recorded. We sought for unpublished trials completed before 2011 through electronic searches and discussions with other experts in the fi eld, but did not fi nd any. (As of Jan 1, 2013, we still know of no such trials completed since 2010.) We obtained individual participant datasets for all 49 621 participants in the 13 trials [21] [22] [23] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] completed by the end of 2010 (table 1, appendix p 6). Information about cancer incidence was not recorded in two other trials 36, 37 with a total of 5992 participants. The protocol for trial identifi cation, analysis and involvement of trialists was agreed following discussion with all collaborators before any cancer results emerged. 19, 20 Baseline and follow-up data For each participant, we requested information about characteristics recorded before randomisation, allocated treatment, and the type and date (or time from randomisation) of any cancer incidence or mortality during the scheduled treatment period. Information about admissions to hospital and cancer incidence was obtained in each trial at 3-6 month intervals during the scheduled treatment period. Self-reported cancer was recorded, and additional infor mation on cancer incidence was, where possible, [28] [29] [30] 35 ob tained from national cancer registries. In one trial, 31 the site of cancer onset was not recorded in the primary database, so we searched all relevant databases of adverse events in that trial to identify incident cancers. The other trials all sought verifi cation of incident cancers from hospital electronic records or by writing to hospital or family physicians. Sites of cancer onset were available for 93% (3446/3713) of the cases.
We checked analyses of the individual participant data for consistency with any published reports and checked them with the trialists to ensure that the data were incorporated correctly into the meta-analysis. We asked investigators to confi rm summary data for every treat ment group on the number of randomised participants, on plasma concentrations of folate and homocysteine before and after start of treatment, and on the number of participants who developed each of the predefi ned outcomes.
The main outcome was incident cancer, defi ned as the fi rst occurrence after randomisation, but during the scheduled treatment period, of any cancer (ignoring nonmelanoma skin cancer). Where cancer was diagnosed only at death and no other information was available, we recorded the date of diagnosis as the date of death. Where cancer site was available only for mortality, we used this for analyses of incidence as well as mortality. We subdivided cancers into the 17 most common types, on the basis of the International Classifi cation of Disease-10 (ICD-10), with the aggregate of all other types as the 18th category, and missing cancer code as the 19th category. Having individual participant data from every trial facilitated uniform categorisation of cancer types (and permitted analyses of treatment eff ects in prespecifi ed subgroups).
Statistical analyses
We based comparisons of cancer rates by allocated treatment on intention-to-treat analyses of fi rst events 
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during the scheduled treatment period to calculate the event rate ratio (RR). The log-rank observed minus expected (o-e) statistics from each trial and their variances (v) were separately summed to produce, respectively, a grand total o-e statistic (G) and its variance (V). 38 The one-step estimate of the log of the RR is then G/V with variance 1/V (and 95% CI G/V±1·96/√V). For n trials, a χ² statistic for heterogeneity with n-1 degrees of freedom (χ² n-1 ) is S-G²/V, where S is the sum over all trials of (o-e)²/v.
We assessed the eff ects on cancer incidence in subgroups of year of follow-up (fi rst 3 years or later), age, sex, plasma folate concentration, plasma homocysteine concentration, and whether or not there was a nationwide folic acid fortifi cation programme. We investigated heterogeneity of the RRs in these subgroups by a global χ² test to reduce the chance of misinterpreting any false positive results arising from multiple com parisons. 39 We used 99% CIs for individual trials or subgroups (again to avoid misinterpreting false positive results), but used 95% CIs for the overall fi ndings. To correct for multiple comparisons, p values for particular types of cancer were multiplied by the number of types investigated (to a maximum corrected p value of 1·0). 40, 41 To help reassess the hypotheses of increased incidence of colorectal adenoma and prostate cancer raised by AFPPS, 21 we assessed the eff ects of folic acid on colorectal and prostate cancer with and without exclusion of the AFPPS trial. 40, 41 The provision of (o-e) for each trial facilitates sensitivity analyses that exclude or include particular trials.
Folate reduces homocysteine, and the mean reduction in all trials was the weighted mean of study-specifi c percent reductions in homocysteine, with weights proportional to the variances of the log-rank statistics for overall cancer incidence. We used Statistical Analysis System (SAS) version 9.2.
Role of the funding source
The sponsors had no role in study design, data collection, data analysis, data interpretation, or writing or submission of the report. The Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) authors had full access to all the data and analyses and accept responsibility for this report. Final analyses and a draft report were circulated to all authors, revised and re-circulated. All authors are responsible for the decision to submit for publication.
Results
Individual participant datasets were obtained from all 13 trials [21] [22] [23] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] that met the inclusion criteria, including in total 49 621 participants (2652 from three trials [21] [22] [23] in patients with a previous colorectal adenoma and 46 969 from ten trials [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] in people with, or at high risk of, cardiovascular disease; table 1). Two-thirds of the participants were men, and the mean age at entry was 64 (SD 10) years (appendix p 6). The daily doses of folic acid ranged from 0·5 mg to 5 mg, except in one trial 27 of a 40 mg daily dose (table 1). All trials compared the eff ects of folic acid versus placebo, except one trial 31 that compared analyses of 2·5 mg versus 0·02 mg (5% of the recommended dietary intake; roughly equivalent to placebo). Mean scheduled treatment duration in diff erent trials varied from 1·8 to 7·4 years, with weighted average 5·2 years.
Allocation to folic acid was associated with quadrupling median plasma concentrations of folate (57·3 nmol/L for folic acid vs 13·5 nmol/L for placebo; except in the one trial of high-dose folic acid, 27 where treatment produced more than a hundred-fold increase in plasma folate). It was also associated with a reduction by a quarter in plasma homocysteine con centrations (9·3 μmol/L for folic acid vs 12·3 μmol/L for placebo; except in the one trial where the pre-treatment homocysteine was already low, 21 where treatment produced little further eff ect on it; appendix p 7). As expected, eff ects on plasma homocysteine concentrations appeared to be somewhat greater in populations not fortifi ed with folic acid (27% reduction) than in fortifi ed populations (20% reduction; appendix p 7). 20 Information was available on 3713 patients with an incident cancer during the scheduled treatment period. Allocation to folic acid treatment did not have any signifi cant eff ect on overall cancer incidence, with 1904 (7·7%) fi rst events in 24 799 participants allocated folic acid versus 1809 (7·3%) in 24 822 allocated control (RR 1·06; 95% CI 0·99-1·13, p=0·10: fi gure 1). No signifi cant heterogeneity was noted between the results of all 13 trials or between the two subtotals for adenoma trials and vascular trials (fi gure 1).
Importantly, we found no evidence of an increasing eff ect of folic acid with increasing duration of treatment (fi gure 2), although only four 21,23,33,35 of the trials lasted more than 5 years. There were no signifi cant diff erences 
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Favours control Favours treatment 99% CI 95% CI by sex, age, pretreatment blood concen tration of folate, pretreatment blood concentration of homocysteine, folic acid fortifi cation in the population, folic acid dose, or percent homocysteine reduction (appendix pp 4-5). Even in the trial 27 of 40 mg/day of folic acid, which produced more than a hundred-fold increase in plasma folate, no apparent increase was noted in overall cancer incidence (65 cancers in the folic acid group vs 72 cancers in the placebo group, RR=0·94; 99% CI 0·61-1·47; fi gure 1).
We classifi ed the 3713 cancers into 18 main types. There was no signifi cant eff ect of folic acid allocation compared with placebo on the incidence of colorectal cancer, lung, breast cancer, prostate cancer, any of the less common types, or cancer of an unknown type, either overall or by treatment duration (fi gure 3, table 2).
Although there were conventionally signifi cant protective eff ects against oesophagus cancer during the fi rst 3 years but not later, and against breast cancer after 3 years but not during the fi rst 3 years (fi gure 3), these unanticipated period-specifi c protective eff ects ceased to be signifi cant when corrected for multiple comparisons (table 2). For adverse eff ects, however, even before any such corrections, there were no conventionally sig nifi cant hazards for any type of cancer in either time period.
The appendix (pp 9-10) gives the log-rank statistics for colorectal and prostate cancer separately for each trial. We repeated the analyses after exclusion of the AFPPS trial, 21 which had reported a signifi cant excess risk of colorectal adenomas and prostate cancer. Overall, the remaining trials did not support a signifi cant adverse eff ect on colorectal cancer (1·08; 95% CI 0·89-1·30; heterogeneity [AFPPS 21 vs the other trials] χ² 1 =0·28, p=0·6) or prostate cancer (1·11; 95% CI 0·95-1·30; heterogeneity [AFPPS 21 vs the other trials] χ² 1 =4·46, p=0·03). The provision of (o-e) for each trial (appendix pp 9-11) facilitates additional sensitivity analyses that exclude particular trials.
Discussion
Both the hopes for rapid cancer prevention and the fears about rapidly increased cancer risk from folic acid supplementation were not confi rmed by this meta-analysis of the trials of folic acid supplementation. Although the point estimate for overall cancer incidence was slightly increased, this fi nding was compatible with a chance eff ect, and the risk did not seem to increase with duration of treatment or daily dose of folic acid. Taking all studies together, allocation to folic acid for an average duration of 5 years had no signifi cant eff ect on overall or site-specifi c cancer incidence during the scheduled treatment period. 
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Par ticularly, supplementation had no signifi cant eff ect on the incidence of cancers of the large intestine (despite the epidemiological evidence of protection), 18 prostate, lung, breast, or any other specifi c site, either over all time periods or during the period more than 3 years after randomisation, although the power to detect diff erences for cancer at particular sites at varying intervals of follow-up was limited. The results of the present meta-analysis, including 49 621 participants, are unlikely to be biased by the unavailability of data on cancer incidence from two small trials, one of 1882 participants testing treatment with folic acid for 2 years 36 and the other 37 of 4110 participants testing treatment with folic acid for 4 years. Inclusion of the few cancer deaths recorded in those two trials would not materially alter the present meta-analyses of cancer incidence in all other trials.
A previous meta-analysis using summary data from a subset of the trials suggested a marginally signifi cant excess of prostate cancer. 42 The present meta-analysis, however, which used individual participant data in a timeto-event analysis from all large trials, showed no signifi cant excess of prostate cancer or of any other type of cancer. Thus, the apparent excess risk of prostate cancer from folic acid supplementation in the results of the AFPPS trial 43 was most likely produced or exaggerated by the play of chance. Appropriate interpretation of such fi ndings requires avoidance of unduly selective emphasis on particular trials, which can be achieved by analysing all trials, and by testing the hypothesis after excluding the results of the trial that generated the hypothesis. 40, 41 For, a striking excess of some type(s) of cancer in some individual trial(s) can be expected by chance alone when many diff erent types of cancer are analysed separately in many diff erent trials.
Although many of the trials used com binations of B vitamins (vitamin B12 and vitamin B6 in addition to folic acid), it is unlikely that this would have concealed any eff ects of folic acid alone on cancer rates. The median daily dose of folic acid in the trials was 2·0 mg, which is greater than in most widely used vitamin supplements (0·1-0·8 mg) and an order of magnitude greater than the dose typically delivered by fl our fortifi cation programmes (0·1-0·4 mg). 8 Despite the low doses provided by fortifi cation, it had been suggested that transient increases in colorectal cancer incidence in Canada and the USA in 1996-98 (during the 3-year period in which nationwide intro duction of folate fortifi cation was being established) might have been due to folic acid. 24 Although the increases in incidence of colorectal cancer recorded in the SEER cancer registries in the USA during 1996-98 are unexplained, they occurred too soon to be plausibly ascribable to the introduction of folate fortifi cation during 1996-98, and did not persist after 1998. Moreover, national trends in mortality from colorectal cancer in the USA at ages 35-69 years (which are unlikely to be infl uenced by any artifactual trends in cancer detection or registration rates) showed no evidence of any new hazard after the introduction of fortifi cation (fi gure 4). Likewise, examination of US mortality rates at ages 35-69 years from the other main types of cancer (data not shown) provides no good evidence of any hazard following fortifi cation. Our meta-analyses included all large trials of folic acid, but the power to exclude benefi cial or adverse eff ects on cancer at individual sites was limited by the number of cancers and the short duration of follow-up in these trials. Although the present meta-analyses address the eff ects of folic acid supplementation on cancer during the scheduled trial treatment period, they do not address the question of whether any benefi cial or harmful eff ects on cancer incidence will eventually emerge among the participants many years after the trials all ended. Followup for decades after the end of the trials might be feasible, especially in populations with automated record linkage to cancer registries and causes of death, but again, it will be important not to place unduly data-dependent emphasis on the results for specifi c types of cancer in individual trials after particular follow-up durations.
Nevertheless, the human evidence about folic acid and cancer that has impeded folic acid fortifi cation in the UK and some other countries involved possible increases in incidence of colorectal and prostate cancer within just the fi rst few years of starting treatment, which, if real, should have been detectable during the trials. The present meta-analyses (which include the hypothesisgenerating trial) address this issue directly, showing that in aggregate, the trials provide no signifi cant evidence of short-term eff ects of folic acid supplementation on overall cancer incidence, or on the incidence of any particular type of cancer. The present meta-analysis rules out moderate increases in overall cancer incidence from folic acid supplementation during the trials. Large increases during the trials in any of the common types of cancer are similarly unlikely. Nationwide dietary fortifi cation involves doses of folic acid that are an order of magnitude lower than the doses studied in these trials. Fortification of flour and all cereal products, 1996-98 Men Women
